

Figure S1. (A) Immunoblot analysis of lysates of stable murine podocyte cell lines expressing PON2-specific shRNA targeted to the 3'UTR of PON2 (PON2 shRNA), scrambled shRNA (control shRNA), and a murine podocyte cell line expressing PON2 shRNA and wildtype murine PON2 lacking the 3'UTR (PON2 shRNA + PON2wt). (B) Low magnification view of PON2-proficient and PON2-deficient mouse podocytes stained with phalloidin.




Figure S2. Phalloidin staining of PON2-proficient and -deficient podocytes after treatment with varying doses of capsazepine in calcium-free PBS. Capsazepine (Capsa) treatment results in reorganization of the actin cytoskeleton in PON2-deficient cells and reversion of the spiked phenotype to round morphology.